IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, November 2024

Review of Nitric Oxide Releasing Delivery Platform

Saurabh Sanjay Gaikwad, Aniket Prabhu Pawar, Vaidesh Vaijnath Gudup
Pratiksha Parasram Shinde, Bhakti Narayan Bodke, Prof. Manisharamesh Virkar
Gajanan Maharaj College of Pharmacy, Chh. Sambhajinagar, India
ssgpatil21@gmail.com

Abstract: *This study presents a novel nitric oxide (NO) releasing delivery platform designed to enhance therapeutic efficacy in various biomedical applications. Utilizing biocompatible materials, the platform provides controlled release of NO, a molecule known for its diverse roles in cellular signaling and vascular function. The delivery system was optimized for stability and release kinetics, demonstrating effective NO release under physiological conditions. In vitro studies indicate improved cellular responses, including enhanced vasodilation and anti-inflammatory effects. This platform holds potential for applications in wound healing, cardiovascular therapies, and other areas where NO's biological properties can be harnessed. Further in vivo investigations will be crucial for assessing the platform's effectiveness and safety in clinical settings. Nitric oxide (NO•) is a free radical gas, produced in the human body to regulate physiological processes, such as inflammatory and immune responses. It is required for skin health; therefore, A lack of NO• is known to cause or worsen skin conditions related to three biomedical applications—Infection treatment, injury healing, and blood circulation. Therefore, research on its topical release Has been increasing for the last two decades. The storage and delivery of nitric oxide in physiological Conditions to compensate for its deficiency is achieved through pharmacological compounds called NO-donors. These are further incorporated into scaffolds to enhance therapeutic treatment. A wide Range of polymeric scaffolds has been developed and tested for this purpose. Hence, this review Aimsto give a detailed overview of the natural, synthetic, and semisynthetic polymeric matrices That have been evaluated for antimicrobial, wound healing, and circulatory dermal applications. These matrices have already set a solid foundation in nitric oxide release and their future perspectiveIs headed toward an enhanced controlled release by novel functionalized semisynthetic polymer Carriers and co-delivery synergetic platforms. Finally, further clinical tests on patients with the Targeted condition will hopefully enable the eventual commercialization of these systems.*

Keywords: Here are some key keywords related to nitric oxide releasing delivery platforms: Nitric oxide(NO),Drug deliver, Nanoparticles

I. INTRODUCTION

Nitric oxide (NO) is a crucial signaling molecule with various physiological roles, including vasodilation, neurotransmission, and immune response. An NO-releasing delivery platform is designed to provide controlled release of nitric oxide for therapeutic applications.

These platforms can take various forms, such as nanoparticles, hydrogels, or polymer-based systems, and are engineered to release NO in response to specific stimuli (e.g., pH, temperature, or enzyme activity). This controlled release enhances the effectiveness of NO in treating conditions like cardiovascular diseases, wound healing, and bacterial infections.

Recent advancements in materials science and nanotechnology have improved the stability and delivery efficiency of these platforms, allowing for targeted and sustained release. The development of such systems aims to maximize the therapeutic benefits of nitric oxide while minimizing side effects, making them promising candidates for various biomedical applications.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, November 2024

Nitric oxide is a free radical molecule that is produced endogenously in the humanBody. Its chemical properties make it suitable for the regulation of several physiologicalProcesses, including circulatory, immune, neurological, and antioxidant responses [1]. Given its widespread participation in biological systems, inadequate amounts of it (bothDeficiency and overproduction) can result in illness [2]. While an excess of nitric oxide isImplicated in hypersensitive responses and neurodegenerative disorders, its lack resultsIn cardiovascular and neurological complications, hypertension, sexual dysfunction, etc.,Especially for patients with a pre-existing condition such as diabetes [3,4].This has brought special interest in the generation of biomedical strategies that carryAnd deliver nitric oxide, or its precursors, exogenously. Being a gaseous free radical, itHas a short half-life in vivo; hence, the main challenges for its administration in the clinicAre stable storage and controlled release. This has led to the blending of nitric oxideDonors with carriers. Numerous of these platforms have been developed where polymerScaffolds are often used [3]. Their physicochemical properties as well as their loading andRelease capacities have been studied and improved in the course of the past 20 years.Polymers are a strong pillar of drug delivery technologies given that they can offerIntrinsic therapeutic activity, be biodegradable to prevent accumulation or toxicity, andEnhance release kinetics. Moreover, their molecular structure can be engineered for morebiocompatibility and strict control over a wide range of drugs. This tunable release canBe in constant doses over long periods, cycled, or condition-responsive, all of which canImprove the therapeutic value of the system [5]. This is by the enhancement of moleculeTransport and because they can become active participants in the treatment. For instance,Their biocompatibility can contribute to increased stability for cellular uptake .

The Inherent properties of the materials vary according to their origin, while synthetic polymersSuch as poly(ethylene oxide) (PEO) and poly(vinyl alcohol) (PVA) are characterized byTheir reproducibility and desirable mechanical properties, natural polymers includingChitosan, alginate, and gelatin, are valuable due to their biocompatibility, biodegradability,Mucoadhesion and antibacterial capacity, for instance [6].Considerable advances in polymer synthesis have contributed to the availability of aWide range of polymeric scaffolds with different architectures (multi-layered, compartmentalized, branched, etc.). These platforms have advanced regarding physical properties byParticle entrapment, with the possibility to tune the capsule size and concerning chemical Advances that allow for surface functionalization, all of which contribute to controlledRelease kinetics [7]. Further improvement in polymer carrier systems has been addressed byThe introduction of semisynthetic polymers, where both natural and synthetic polymers areLinked to each other to obtain a combination of their properties. Along with the evolution ofPolymers, the therapeutic effect of drug co-delivery by different release triggers is anotherIncreasing trend that has accomplished synergistic treatments.

Dermal (cutaneous) administration of NO-donors has been increasingly studied asA promising therapy for related skin conditions. The endogenous synthesis of nitric Oxide in human skin can be either enzymatic or chemical and it is required for variousProcesses such as pigmentation, blood flow dynamics, cutaneous tissue regeneration, andSkin immune response [3,8]. The focus of this review consists of the topical NO-deliveryBy polymer matrices according to their application target, with a special highlight onThe nature of the applied polymers. For a better understanding of these platforms, anOverview of the biochemistry and the dermatological role of nitric oxide, and the resultingDisorders is given in the upcoming sections (Sections 2–4). Afterward, nitric oxide donorsAnd their possible carriage systems are explained (Sections 5 and 6) before reviewing thePharmaceutical dermal applications in detail (Section 7). Finally, remarks are made on the Future perspectives of these technologies (Section 8).

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, November 2024



FIG:-1. NITRIC OXIDE SYNTHASE

History:

The history of nitric oxide (NO) releasing delivery platforms spans several decades, intertwining advancements in biochemistry, pharmacology, and materials science. Here's a concise overview:

Early Discoveries

1980s: The biological role of nitric oxide was established, particularly in vascular biology. NO was identified as a signaling molecule involved in vasodilation, primarily through the work of researchers like Robert Furchgott, Louis Ignarro, and Ferid Murad, who later won the Nobel Prize in Physiology or Medicine in 1998.

Development of Delivery Platforms

1990s: Researchers began exploring ways to deliver NO therapeutically. Early studies focused on gaseous NO for treating pulmonary hypertension, but challenges with stability and dosage led to the need for more controlled delivery systems.

1998: The first synthetic NO donors, such as nitroglycerin and sodium nitroprusside, were widely used, but they had limitations related to side effects and the duration of action.

Innovative Approaches

2000s: Advances in polymer science led to the development of biodegradable polymers and hydrogels capable of controlled NO release. Researchers explored various materials, including polyurethanes and silicone, to create localized delivery systems for cardiovascular and wound healing applications.

2010s: The focus shifted towards nanoparticles and nanoscale delivery systems. These platforms allowed for more targeted and sustained release of NO, improving therapeutic outcomes in conditions like ischemia and infections.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, November 2024

Recent Advances

2020s: New technologies, including NO-releasing coatings for medical devices and scaffolds for tissue engineering, have been developed. These platforms not only deliver NO but also facilitate healing and reduce infection rates in surgical applications.

Current Trends and Future Directions

Ongoing research is investigating the synergy of NO with other therapeutics and its potential in cancer therapy, regenerative medicine, and combating antibiotic resistance. The goal is to optimize delivery systems for efficacy, safety, and patient compliance.

Inhalation

Respiratory Tract: When inhaled, NO diffuses rapidly across the alveolar membrane into the bloodstream due to its small size and high lipid solubility.

Gas Exchange: Once in the lungs, NO can quickly reach systemic circulation, where it plays a crucial role in vasodilation and other physiological processes.

Endogenous Production

Cellular Sources: NO is produced in the body from the amino acid L-arginine via nitric oxide synthase (NOS) enzymes. It diffuses directly from the cells where it is synthesized into surrounding tissues and blood vessels.

Absorption and Distribution:

Systemic Effects: Once absorbed, NO interacts with smooth muscle cells, leading to vasodilation and increased blood flow. It also acts as a signaling molecule in various physiological processes.

Factors Affecting Absorption

Concentration and Form: The absorption rate can be influenced by the concentration of NO and the method of delivery (e.g., inhaled gas vs. NO donors)Pathophysiological Conditions: Conditions such as pulmonary hypertension or respiratory disorders can affect the efficiency of NO absorption and its subsequent effectsAdvantages:Nitric oxide (NO) offers several significant advantages in various physiological and therapeutic contexts .

Vasodilation

Improved Blood Flow: NO relaxes vascular smooth muscle, leading to widened blood vessels and enhanced blood circulation, which is beneficial for conditions like hypertension and angina.

Cardiovascular Health

Reduced Blood Pressure: By promoting vasodilation, NO helps lower blood pressure and improves overall cardiovascular health.Prevention of Platelet Aggregation: NO inhibits platelet activation, reducing the risk of thrombosis.

Respiratory Benefits.

Pulmonary Vasodilation: Inhaled NO can selectively dilate pulmonary vessels, making it useful in treating conditions like pulmonary hypertension and acute respiratory distress syndrome (ARDS).

Immune Response

Antimicrobial Properties: NO plays a role in the immune response, helping to kill pathogens and modulate inflammation, which can be beneficial in infections.

Wound Healing

Enhanced Tissue Repair: NO promotes angiogenesis (formation of new blood vessels) and collagen synthesis, aiding in wound healing and tissue regeneration.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, November 2024

Neurotransmission

Signaling Molecule: NO functions as a neurotransmitter in the brain, involved in processes such as memory and learning.

Performance Enhancement

Exercise Tolerance: NO supplementation may improve exercise performance by enhancing blood flow and oxygen delivery to muscles.

Potential in Cancer Therapy

Targeted Treatment: Research is exploring NO's role in selectively targeting cancer cells, potentially reducing tumor growth and enhancing the effectiveness of certain chemotherapeutics.

Disadvantages:While nitric oxide (NO) has numerous benefits, it also presents several disadvantages and potential risks:

1. Short Half-Life

Rapid Decomposition: NO has a very short half-life (seconds to minutes), which can make it challenging to maintain effective therapeutic levels in the body

2. Toxicity at High Levels

Cytotoxic Effects: Elevated levels of NO can lead to oxidative stress and damage to tissues, contributing to conditions like inflammation and neurodegeneration.

3. Potential for Nitrosative Stress

Formation of Reactive Species: NO can react with superoxide to form peroxynitrite, a reactive nitrogen species that can cause cellular damage and is implicated in various diseases.

4. Limited Stability in Formulations

Difficult to Store: NO is a gas that is challenging to store and handle in pharmaceutical formulations, complicating its use in medical settings.

5. Variable Responses

Individual Differences: Responses to NO can vary significantly among individuals, influenced by factors such as genetics, underlying health conditions, and concurrent medications.

6. Drug Interactions

Complicated Therapeutic Regimens: NO can interact with other medications, particularly those affecting blood pressure and vascular tone, leading to unpredictable effects.

7. Potential for Tolerance

Diminished Efficacy Over Time: Prolonged use of NO donors may lead to tolerance, reducing their effectiveness in managing conditions like angina.

New generation of nitric oxide-releasing porous materials

The development of new nitric oxide (NO)-releasing porous materials is a fascinating area of research, particularly for applications in biomedical fields, catalysis, and environmental science. NO has various biological roles, including in wound healing, antimicrobial activity, and vascular relaxation, which makes it valuable for therapeutic uses.

Recent advancements focus on designing porous materials—such as metal-organic frameworks (MOFs), porous polymers, and silica-based materials—that can store and release NO in a controlled manner. These materials are being engineered to have specific pore sizes, surface areas, and chemical properties to optimize NO storage and release rates. Researchers are exploring ways to make the release process responsive to environmental triggers like pH, light, or temperature, which allows for more targeted NO delivery.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, November 2024



Method and material of Nitric oxide Releasing delivery platform:Methods

Chemical Donors:-

Organic Nitrate Compounds: Substances like nitroglycerin or isosorbidedinitrate releaseNO upon enzymatic or chemical conversion in the body.

S-nitrosothiols: These compounds release NO upon reaction with biological thiols, providing a sustained release profile.

Polymer-Based System:-

Biodegradable Polymers: Polymers such as poly(lactic-co-glycolic acid) (PLGA) can be engineered to encapsulate NO donors, releasing NO over time through hydrolysis or degradation.

Hydrogels: Crosslinked networks can trap NO donors, releasing them in response to changes in pH or temperature.

Nanoparticle Systems

Metal Nanoparticles: Gold or silver nanoparticles can be functionalized with NO donors to allow controlled release triggered by environmental changes.

Lipid-Based Nanocarriers: Liposomes can encapsulate NO donors, providing a targeted delivery mechanism that releases NO in specific tissues.

Coatings and Surface Modifications

NO-Releasing Coatings: Medical devices can be coated with materials that release NO, helping to reduce thrombosis and infection rates.

Surface Functionalization: Modifying surfaces of implants or scaffolds with NO-releasing materials can enhance biocompatibility and tissue integration.

Polymers

PLGA: Biodegradable and allows for controlled drug release.

Polyurethane: Flexible and can be tailored for various applications.

Chitosan: Biocompatible and can be used in hydrogels.

NO Donors

S-nitrosoglutathione (GSNO): A naturally occurring NO donor that releases NO upon hydrolysis.

DiethylamineNONOate (DEA/NO): A commonly used synthetic NO donor with predictable release profiles.

Nanomaterials

Gold and Silver Nanoparticles: Used for targeted delivery and enhanced stability of NO.

Silica Nanoparticles: Functionalized to release NO in a controlled manner.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, November 2024

Hydrogels
Alginate: Biocompatible and can be used for sustained NO release.
Polyethylene glycol (PEG): Offers tunable release rates and biocompatibility.

Application :
Nitric oxide (NO) releasing delivery platforms have diverse applications across various medical fields due to their unique biological properties. Here are some key applications:

Cardiovascular Medicine
Angina and Hypertension Treatment: NO donors are used to manage conditions like angina pectoris and hypertension by promoting vasodilation, improving blood flow, and reducing blood pressure.
Coronary Artery Disease: NO-releasing agents help prevent platelet aggregation and thrombosis, potentially reducing the risk of heart attacks.

Pulmonary Disorders
Pulmonary Hypertension: Inhaled NO is used to selectively dilate pulmonary blood vessels, improving oxygenation and blood flow in conditions like pulmonary arterial hypertension.

Acute Respiratory Distress Syndrome (ARDS): NO can improve ventilation-perfusion mismatch in ARDS by dilating pulmonary vessels.

Wound Healing
Enhanced Tissue Repair: NO promotes angiogenesis and collagen synthesis, aiding in the healing of chronic wounds, diabetic ulcers, and surgical incisions.
Antimicrobial Activity: The release of NO can help reduce bacterial load in infected wounds, enhancing healing.

Orthopedic Applications
Bone Healing: NO delivery platforms can enhance osteogenesis and bone repair, making them useful in treating fractures and bone defects.
Implants and Prosthetics: NO-releasing coatings on orthopedic implants can reduce infection rates and improve integration with surrounding tissue.

Cancer Therapy
Tumor Targeting: NO has potential in selectively targeting cancer cells, potentially enhancing the efficacy of chemotherapeutics and reducing tumor growth.
Combination Therapy: NO can sensitize cancer cells to radiation and other treatments, improving overall therapeutic outcomes.

Neuroprotection
Cognitive Disorders: NO plays a role in neurotransmission and may be used in therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
Stroke Management: Controlled release of NO can protect neurons from ischemic damage during strokes.

Infection Control
Antimicrobial Properties: NO's ability to kill bacteria, viruses, and fungi makes it a candidate for treating infections, particularly in wound care and respiratory conditions.
Biofilm Disruption: NO can penetrate biofilms formed by bacteria, enhancing the efficacy of antibiotics.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, November 2024

Dental Applications

Periodontal Disease Treatment: NO-releasing agents can help manage gum diseases by promoting healing and reducing inflammation.

Root Canal Therapy: NO can enhance the disinfection of root canals due to its antimicrobial properties.

Cosmetic Applications

Anti-Aging Treatments: NO's role in promoting blood flow and cellular activity is being explored in cosmetic formulations to improve skin health and appearance.

Safety of Nitric oxide Releasing delivery platform:

Safety Considerations for Nitric Oxide Releasing Delivery Platforms

When developing and using nitric oxide (NO) releasing delivery platforms, safety is paramount due to the potent biological effects of NO. Here are key **safety considerations:**

Toxicity of Nitric Oxide

Oxidative Stress: High concentrations of NO can lead to the formation of reactive nitrogen species, which may cause oxidative stress and cellular damage.

Dose-Dependent Effects: Proper dosing is critical; while low concentrations can be therapeutic, high levels can be toxic.

Delivery Mechanism Safety

Controlled Release: The design of the delivery system should ensure that NO is released in a controlled manner to avoid spikes in concentration that could lead to toxicity.

Biocompatibility of Materials: Materials used in the delivery platform (polymers, coatings) must be biocompatible to minimize adverse reactions when interacting with body tissues.

Monitoring and Assessment

In Vivo Monitoring: Continuous monitoring of NO levels and its effects in clinical applications is essential to avoid complications.

Preclinical Testing: Extensive preclinical studies should assess the safety and efficacy of NO releasing systems before clinical use.

Potential Side Effect

Hypotension: Due to its vasodilatory effects, there is a risk of hypotension (low blood pressure), particularly in sensitive populations.

Headaches and Flushing: Common side effects from NO donors include headaches and facial flushing, necessitating monitoring and patient education.

Patient Selection

Contraindications: Certain conditions (e.g., severe hypotension, recent myocardial infarction) may contraindicate the use of NO releasing systems.

Individual Variability: Patients may respond differently to NO, and pre-existing conditions should be considered in treatment plans.

Environmental Stability

Storage Conditions: NO and its donors should be stored properly to maintain stability and efficacy. Degradation products must be assessed for potential toxicity.

Compatibility with Other Therapies: NO can interact with other medications, which should be evaluated to prevent adverse effects.

Regulatory Approval

Compliance with Standards: NO releasing delivery systems must comply with regulatory standards set by health authorities (e.g., FDA, EMA) to ensure safety and efficacy.

Post-Market Surveillance: Ongoing monitoring of safety and effectiveness after market release is crucial to identify any long-term risks.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 4, November 2024

II. CONCLUSION

Nitric oxide (NO) releasing delivery platforms represent a promising advancement in therapeutic medicine, offering significant benefits across various fields such as cardiovascular health, wound healing, pulmonary disorders, and cancer therapy. The ability to control the release of NO enhances its efficacy while minimizing potential side effects, making these platforms valuable tools in clinical practice.

However, the successful implementation of NO delivery systems requires careful consideration of safety, dosing, and material biocompatibility. Ongoing research is essential to optimize these platforms, ensuring that they deliver therapeutic levels of NO effectively while minimizing toxicity.

As our understanding of NO's biological roles expands, so too does the potential for innovative applications, from improving patient outcomes to addressing unmet medical needs. The continued development of NO releasing delivery platforms is poised to play a crucial role in advancing modern medicine, ultimately enhancing the quality of care for patients.At present, we are not aware of clinical trials or late-stage

Preclinical development of NO-releasing implantable bioma-Terials.

To our eyes, academic developments presented above Are highly successful. Translational prospects also appear good: Many biomaterials discussed above were developed with knowl-Edge of successful biomaterials for clinical use[136,137] and some NO donors are approved for use in humans. However, markets,

e.g., cardiovascular stents or catheters (noted here as some of the examples where NO-releasing biomaterials could find (commercial utility) are occupied by successful products, and bringing an innovation to the market is hard.

REFERENCES

[1]. D. E. Koshland, Science 1992, 258, 1861.
[2]. J. O. Lundberg, M. T. Gladwin, E. Weitzberg, Nat. Rev. Drug Discovery2015, 14, 623.
[3]. C. Bogdan, Nat. Immunol. 2001, 2, 907.
[4]. V. Calabrese, C. Mancuso, M. Calvani, E. Rizzarelli, D. A. Butterfield, A.M. G. Stella, Nat. Rev. Neurosci. 2007, 8, 766.
[5]. J. Y. H. Chang, W. D. Stamer, J. Bertrand, A. T. Read, C. M. Marando, R. Ethier, D. R. Overby, Am. J. Physiol. Cell Physiol. 2015, 309, C205.
[6]. M. W. Radomski, R. M. J. Palmer, S. Moncada, Biochem. Biophys. Res. Commun. 1987, 148, 1482 L. J. Hofseth, Cancer Lett., 2008, 268, 10.
[7]. T. Tor € ok, € Physiol. Res., 2008, 57, 813.
[8]. K. Thermos, Mol. Cell. Endocrinol., 2008, 286, 49.
[9]. S. Chatterjee, K. E. Chapman and A. B. Fisher, Cell Biochem.Biophys., 2008, 52, 125.
[10]. A. Vardanian, R. W. Busuttil and J. W. Kupiec-Weglinski, Mol.Med., 2008, 14, 337–345.
[11]. A. Murugan, C. Prys-Picard and W. J. Calhoun, Curr. Opin. Pulm.Med., 2009, 15, 12.
[12]. C. Kim and Y. N. Cha, in Advances in Experimental Medicine andBiology, ed. J. Azuma, S. W. Schaffer and T. Ito, Springer, NewYork, 2009, vol. 643, p. 463.
[13]. T. P. Amadeu, A. B. Seabra, M. G. De Oliveira and A. M. A. Costa,J. Eur. Acad. Dermatol. Venereol., 2007, 21, 629.15 F. Murad, www.pitt.edu super7/14011-15001/14451.ppt, SuperCourse Golden Lecture of Prevention; http://www.bibalex.org/ Supercourse/lecture/lec14451/index.htm, 2004.